Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hexavalent Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $3.6 million
Deal Type : Funding
VitriVax Awarded $3.6M Grant for Polio Vaccine Development
Details : The funding will help VitriVax to applying its proprietary ALTA technology to new polio vaccine candidates composed of virus-like particles (VLPs) for use in future combination hexavalent vaccines.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
December 04, 2024
Lead Product(s) : Hexavalent Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $3.6 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $5.0 million
Deal Type : Funding
VitriVax Receives $5M Grant for Vaccine Development
Details : The company will develop its proprietary single shot, thermostabilization vaccine technology (ALTA™) and will study the ALTA™ mechanism of action using model antigens, such as those targeting HIV.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
December 06, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : Thermostable Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Defense Threat Reduction Agency
Deal Size : $29.0 million
Deal Type : Funding
VitriVax Awarded $29M DoD Contract to Fund Vaccine Research
Details : The funding will be used to apply VitriVax’s ALTA™ platform to the lead B. pseudomallei vaccine candidate, which is currently a three-dose regimen, with the goal of developing a single injection, thermostable vaccine formulation to protect against me...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
July 19, 2023
Lead Product(s) : Thermostable Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Defense Threat Reduction Agency
Deal Size : $29.0 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?